ONKT 102
Alternative Names: ONKT-102Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator ONK Therapeutics; VU University Medical Center
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in Multiple-myeloma in Ireland (Parenteral)
- 29 Aug 2022 Pharmacodynamics data from preclinical studies in Multiple myeloma released by ONK Therapeutics
- 09 Sep 2021 ONK Therapeutics has patent protection for CISH knockout in NK cells for use in cancer therapies in the US